Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • x Monday 29 June 2026 (4)
  • Until platform closure (9)
Poster categories
  • Thematic Poster Session (4)
keywords
Session Reference
  • L-TPS01 (2)
  • L-TPS02 (1)
  • L-TPS03 (5)
  • L-TPS04 (1)
  • L-TPS06 (1)
  • L-TPS07 (6)
  • L-TPS08 (2)
  • L-TPS09 (3)
  • L-TPS10 (4)
  • L-TPS11 (5)
  • L-TPS12 (2)
  • L-TPS13 (4)
  • L-TPS14 (1)
  • L-TPS15 (2)
  • L-TPS16 (2)
  • x L-TPS17 (4)
  • L-TPS18 (4)
  • L-TPS20 (2)
  • L-TPS22 (1)
  • L-TPS23 (1)
  • L-TPS24 (4)
  • L-TPS25 (3)
  • TPS01 (5)
  • TPS02 (2)
  • TPS03 (4)
  • TPS04 (6)
  • TPS05 (3)
  • TPS06 (4)
  • TPS07 (3)
  • TPS08 (3)
  • TPS09 (2)
  • TPS10 (6)
  • TPS11 (7)
  • TPS12 (6)
  • TPS13 (1)
  • TPS14 (6)
  • TPS15 (5)
  • TPS16 (3)
  • TPS17 (4)
  • TPS18 (2)
  • TPS20 (5)
  • TPS21 (4)
  • TPS22 (4)
  • TPS23 (3)
  • TPS24 (4)
  • TPS25 (3)
  • TPS26 (7)
  • TPS29 (1)
  • TPS30 (2)
  • TPS31 (5)
  • TPS33 (2)
  • TPS34 (5)
  • TPS35 (4)
  • TPS36 (3)
  • TPS37 (2)
  • TPS38 (4)
  • TPS39 (3)
  • TPS40 (6)
  • TPS41 (4)
  • TPS42 (3)
  • TPS43 (3)
  • TPS44 (3)
  • TPS45 (1)
  • TPS46 (1)
  • TPS47 (3)
  • TPS48 (1)
  • TPS49 (1)
  • TPS50 (4)
  • TPS51 (6)
  • TPS52 (6)
  • TPS53 (6)
  • TPS54 (3)
  • TPS55 (6)
  • TPS56 (3)
  • TPS57 (1)
  • TPS60 (3)
  • TPS61 (5)
  • TPS62 (3)
  • TPS63 (2)
  • TPS64 (3)
  • TPS65 (1)
  • TPS66 (6)
  • TPS67 (3)
  • TPS68 (6)
  • TPS69 (1)
  • TPS70 (1)
  • TPS71 (1)
  • TPS72 (2)
  • TPS73 (3)
  • TPS74 (2)
  • TPS75 (6)
  • TPS76 (1)
  • TPS77 (1)
  • TPS78 (2)
  • TPS79 (11)
  • TPS80 (3)
  • TPS82 (7)
  • TPS83 (2)
  • TPS84 (4)
  • TPS85 (3)
  • TPS86 (1)
4 results
Thumbnail

D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children

Thumbnail

D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience

Thumbnail

D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid

Thumbnail

D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM